ACR: First-Line RA Drug Linked to Decreased CVD Risk

Share this content:
ACR: First-Line RA Drug Linked to Decreased CVD Risk
ACR: First-Line RA Drug Linked to Decreased CVD Risk
BOSTON -- The antimalaria drug hydroxychloroquine (Plaquenil) that is used as first-line therapy in patients with rheumatoid arthritis (RA) is also associated with reduced cardiovascular risk, especially at higher doses, a new study shows. The retrospective analysis included 514 RA patients ages 18 years or older who were treated at a single institution between 2003 and 2013.
READ FULL ARTICLE From Medical Page Today
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »